Key Takeaways
- Rigetti secured a preliminary agreement with the Department of Commerce for up to $100 million in CHIPS Act funding distributed over three years.
- Shares of RGTI surged nearly 20% on Friday, finishing at $26.42, amid a quantum computing sector-wide rally.
- The federal investment focuses on addressing critical technical obstacles in superconducting quantum systems, including miniaturized chip components and enhanced cryogenic infrastructure.
- The agreement may involve a government equity position, potentially leading to shareholder dilution upon finalization.
- Wall Street maintains a Moderate Buy rating on RGTI with consensus price targets ranging from $29 to $30, suggesting limited near-term upside.
Shares of Rigetti Computing (RGTI) experienced a significant rally on Friday, climbing nearly 20% after the quantum computing company announced a preliminary agreement with the U.S. Department of Commerce for a potential $100 million funding package through the CHIPS Act. The stock concluded trading at $26.42.
This funding allocation represents a portion of a comprehensive $2.013 billion federal initiative authorized under the CHIPS and Science Act, distributed among nine technology companies. The recipient list includes seven quantum computing specialists—D-Wave, PsiQuantum, Quantinuum, and Infleqtion among them—alongside industry giants IBM and GlobalFoundries.
Rigetti’s designated allocation—potentially reaching $100 million across a three-year timeline—will concentrate on advancing and commercializing next-generation superconducting quantum computing platforms. Priority areas include reducing the physical footprint of readout electronics and optimizing cryogenic system design.
CEO Subodh Kulkarni characterized the award as validation from federal leadership. “This capital infusion enables us to address critical scaling challenges with greater velocity and advances our timeline toward commercially viable quantum computing,” he stated.
A notable provision deserves investor attention: the arrangement contemplates a possible government equity position correlated to the funding magnitude. Unlike traditional research grants, this structure provides the federal government with ownership interest in Rigetti’s future performance. Should the agreement reach completion, current shareholders may face equity dilution.
Rigetti’s Technological Differentiation
Rigetti’s fundamental technology relies on superconducting qubits—a methodology similarly employed by IBM and Alphabet, though with distinct implementation. The company utilizes a chiplet-based framework, assembling smaller quantum processors into expanded computational systems.
The company’s 108-qubit Cepheus processor exemplifies this strategy, constructed from twelve discrete 9-qubit chiplets. This modular approach aims to simplify scalability by circumventing manufacturing complexities associated with fabricating monolithic large-scale chips. Gate operation speeds range from 50 to 70 nanoseconds, demonstrating competitive performance relative to alternative quantum methodologies.
This strategic positioning distinguishes Rigetti from IonQ, which implements trapped-ion quantum systems, and from IBM, which commands substantially greater capital resources. Rigetti emphasizes a concentrated value proposition: comprehensive technology stack ownership, high-speed superconducting architectures, and deployment flexibility across cloud and dedicated infrastructure—particularly serving government laboratories requiring air-gapped systems for classified operations.
Wall Street Perspective and Financial Performance
Analyst sentiment leans cautiously positive. Among 13 analysts tracking the equity, eight recommend buying, four maintain hold positions, and one advises selling. Consensus 12-month price projections cluster around $29–$30, suggesting approximately 13% appreciation potential from Friday’s closing level.
Rigetti’s latest quarterly disclosure exceeded market expectations. The company posted earnings per share of -$0.04, outperforming the -$0.05 analyst consensus. Revenue reached $4.4 million, representing 198.9% year-over-year expansion and surpassing the $4.09 million forecast.
The stock benefited from broader quantum sector momentum triggered by the government funding announcement. Competitor stocks IonQ and D-Wave advanced 8% and 14% respectively during the same session. RGTI shares have appreciated approximately 48% on a week-over-week basis.
Benchmark retained its buy recommendation while adjusting its price objective downward from $35 to $25. Rosenblatt maintains a $40 valuation target. The stock’s 52-week trading range spans $10.30 to $58.15, with the 50-day moving average positioned at $16.82.
